Population Pharmacokinetics of Voriconazole and Optimizing Dosing Regimens in Patients with Liver Dysfunction

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800015015

Enrollment

Unknown

Registered

2018-02-28

Start date

2018-03-12

Completion date

Unknown

Last updated

2018-03-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fungal infection

Interventions

High risk group:Artificially divided

mild and moderate group:Child-pugh class

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Using of voriconazole for treatment or prevention fungal infections in patients with liver dysfunction; 2. at least one voriconazole plasma Cmin; 3. Aged more than 18 years.

Exclusion criteria

Exclusion criteria: 1. simultaneous use of another antifungal agent; 2. combination of rifampicin,isoniazid,phenytoin and other potent CYP450 inducers and inhibitors; 3. lack of compliance with the recommended dosage regimen.

Design outcomes

Primary

Measure	Time frame
Blood concentration;Clinical index;	—

Countries

China

Contacts

Public ContactYan Miao

The Second Xiangya Hospital of Central South University?

yan.miao@126.com+86 13787783668

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026